Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer.

[1]  C. V. D. van de Velde,et al.  Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer , 2006, British Journal of Cancer.

[2]  W. Zhan,et al.  Lymph node micrometastasis and its correlation with MMP-2 expression in gastric carcinoma. , 2006, World journal of gastroenterology.

[3]  X. Ji,et al.  DNA ploidy analysis and expression of MMP-9, TIMP-2, and E-cadherin in gastric carcinoma. , 2005, World journal of gastroenterology.

[4]  Yue-liang Chen,et al.  Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. , 2005, World journal of gastroenterology.

[5]  W. Tan,et al.  Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. , 2005, Carcinogenesis.

[6]  R. Ala-aho,et al.  Collagenases in cancer. , 2005, Biochimie.

[7]  S. Barros,et al.  Analysis of the MMP-9 (C-1562 T) and TIMP-2 (G-418C) gene promoter polymorphisms in patients with chronic periodontitis. , 2005, Journal of clinical periodontology.

[8]  M. Lai,et al.  A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. , 2004, Biochemical and biophysical research communications.

[9]  W. Tan,et al.  Functional Haplotypes in the Promoter of Matrix Metalloproteinase-2 Predict Risk of the Occurrence and Metastasis of Esophageal Cancer , 2004, Cancer Research.

[10]  W. Tan,et al.  Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. , 2003, Carcinogenesis.

[11]  P. Pääkkö,et al.  Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker inbladder cancer , 2003 .

[12]  W. Tan,et al.  A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. , 2003, Cancer research.

[13]  Chien-Jen Chen,et al.  Interleukin‐10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese , 2003, International journal of cancer.

[14]  W. Tan,et al.  Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. , 2002, Cancer research.

[15]  M. Pan,et al.  Nonsteroidal Anti-inflammatory Drugs Inhibit Matrix Metalloproteinase-2 via Suppression of the ERK/Sp1-mediated Transcription* , 2002, The Journal of Biological Chemistry.

[16]  I. Goldberg,et al.  Complex roles of tissue inhibitors of metalloproteinases in cancer , 2002, Oncogene.

[17]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[18]  A. Hölscher,et al.  Expression of MMP‐2 is associated with progression and lymph node metastasis of gastric carcinoma , 2001, Histopathology.

[19]  A. Cheng,et al.  Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Sekizawa,et al.  Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. , 2001, The European respiratory journal.

[21]  D. Greaves,et al.  Identification of Novel, Functional Genetic Variants in the Human Matrix Metalloproteinase-2 Gene , 2001, The Journal of Biological Chemistry.

[22]  I. Stamenkovic.  Matrix metalloproteinases in tumor invasion and metastasis. , 2000, Seminars in cancer biology.

[23]  P. Soloway,et al.  TIMP-2 Is Required for Efficient Activation of proMMP-2 in Vivo * , 2000, The Journal of Biological Chemistry.

[24]  M J Bissell,et al.  The influence of the microenvironment on the malignant phenotype. , 2000, Molecular medicine today.

[25]  D. Grignon,et al.  Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  G I Murray,et al.  Matrix metalloproteinases in tumour invasion and metastasis , 1999, The Journal of pathology.

[27]  E. Benveniste,et al.  The Transcription Factors Sp1, Sp3, and AP-2 Are Required for Constitutive Matrix Metalloproteinase-2 Gene Expression in Astroglioma Cells* , 1999, The Journal of Biological Chemistry.

[28]  B. Davidson,et al.  MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. , 1999, Gynecologic oncology.

[29]  V. Kähäri,et al.  Role of thymic peptides as transmitters between the neuroendocrine and immune systems. , 1999 .

[30]  G. Murray,et al.  Matrix metalloproteinases and their inhibitors in gastric cancer , 1998, Gut.

[31]  M. Seiki,et al.  Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. , 1998, Oncology reports.

[32]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[33]  H. P. Wang,et al.  Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. , 1997, Gastroenterology.

[34]  H. Verspaget,et al.  Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. , 1996, British Journal of Cancer.

[35]  Y. Okada,et al.  Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. , 1995, Cancer research.

[36]  P. Hermanek.  pTNM and residual tumor classifications: Problems of assessment and prognostic significance , 1995, World Journal of Surgery.

[37]  F. Sarkar,et al.  Enhanced expression of tissue inhibitor of metalloproteinase‐2 (TIMP‐2) in the stroma of breast carcinomas correlates with tumor recurrence , 1994, International journal of cancer.

[38]  A. Shinagawa,et al.  Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). , 1994, Journal of cell science.

[39]  G. Rousseau,et al.  Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). , 1994, Gene.

[40]  J. Carmichael,et al.  Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. , 1993, Journal of the National Cancer Institute.

[41]  E. Howard,et al.  Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. , 1991, The Journal of biological chemistry.

[42]  A. Cassoni.  Tnm Classification of Malignant Tumours , 1987 .

[43]  J. Nesland,et al.  High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma , 2004, Clinical & Experimental Metastasis.